What Is Aneuploidy Screening and How Does It Work?

Aneuploidy screening is a set of prenatal tests that estimate the chance a pregnancy involves a fetus with an abnormal number of chromosomes, most commonly an extra copy of chromosome 21 (Down syndrome), 18 (Edwards syndrome), or 13 (Patau syndrome). The tests range from blood draws combined with ultrasound measurements to advanced analysis of fragments of fetal DNA circulating in the pregnant person’s blood. None of these screens deliver a definitive yes or no; they produce a risk estimate, and a high-risk result still needs confirmation through a diagnostic procedure like amniocentesis.

Traditional First-Trimester Combined Screening

The earliest screening most people encounter happens between roughly 10 and 14 weeks of pregnancy. It combines two types of information: an ultrasound measurement and a blood test. The ultrasound measures the nuchal translucency, a pocket of fluid at the back of the fetal neck. When that fluid collection is thicker than expected, the risk of certain chromosomal abnormalities goes up. The blood test measures two proteins produced by the placenta and fetus: free beta-hCG and PAPP-A. Unusual levels of those proteins shift the risk estimate for conditions like Down syndrome and other trisomies.¹

The combined screen performs reasonably well, but researchers have found that adding secondary ultrasound markers, such as whether the nasal bone is visible, blood flow patterns in the ductus venosus, and the presence of tricuspid regurgitation, can push the false-positive rate down from around 5% to about 3.4% while maintaining high detection rates.² Fewer false positives means fewer people being sent for invasive follow-up procedures they did not need.

Second-Trimester Blood Screening

Some people undergo screening in the second trimester instead of or in addition to first-trimester screening. The most common version, often called the quad screen, measures four substances in the blood drawn between about 15 and 22 weeks. In a large cohort of around 35,000 women, the quad screen detected about 69% of pregnancies affected by trisomy 18, trisomy 13, or monosomy X, with a false-positive rate near 9%. When gestational age was confirmed by ultrasound and maternal weight was factored in, detection of Down syndrome improved to roughly 79%.³ Those numbers are decent for a blood test alone, but the false-positive rate is higher than what newer cell-free DNA methods achieve, which is one reason the quad screen has been gradually supplanted in many clinical settings.

How Cell-Free DNA Screening Works

The technology behind the newest form of aneuploidy screening, commonly called NIPT (non-invasive prenatal testing), relies on a biological quirk: small fragments of DNA from the placenta constantly spill into the pregnant person’s bloodstream. These fragments, known as cell-free fetal DNA, are released when placental cells undergo a natural process of programmed cell death.⁴ Even though the fragments come from the placenta rather than directly from the fetus, the placenta and fetus share the same genetic material in the vast majority of pregnancies.

A standard NIPT workflow involves drawing a tube of blood from the pregnant person, isolating the cell-free DNA from the plasma, and then sequencing it. One common approach uses whole-genome sequencing to count how many DNA fragments map to each chromosome. If chromosome 21 is slightly over-represented relative to what you’d expect, that suggests the fetus may carry an extra copy. Modern automated platforms can complete the sequencing and analysis within a single day.⁵ The approach screens for aneuploidies of chromosomes 21, 18, 13, X, and Y.

How Reliable Are the Results

NIPT is often described as highly accurate, and for the common autosomal trisomies it is far more sensitive than traditional screening. But the headline sensitivity numbers can obscure a critical nuance: the chance that a positive result is actually correct, known as the positive predictive value, depends heavily on the person’s background risk. In a study that grouped patients by risk level, high-risk individuals (those with two or more risk factors) who screened positive for trisomy 21, 18, or 13 had a true-positive rate above 97%. For low-risk individuals, that number dropped to roughly 36%.⁶

This gap surprises many people. A “positive” NIPT in a younger person with no other risk factors has a much higher chance of being wrong than the same result in an older person with abnormal ultrasound findings. That is not a failure of the test so much as a mathematical reality: when the condition you are looking for is rare in your group, even a very good test produces more false alarms relative to true catches. This is the single most important thing to understand about any screening result.

Why False Positives and False Negatives Happen

NIPT reads DNA from the placenta, not the fetus directly, and sometimes the two don’t match. A condition called confined placental mosaicism, where the placenta carries an abnormal chromosome count but the fetus does not, is one of the most common biological causes of a false positive. The reverse can also happen: the fetus has the aneuploidy but the placenta does not, leading to a false negative.⁷

Beyond placental mosaicism, several other factors can throw results off. Low fetal fraction, meaning the proportion of cell-free DNA in the sample that actually comes from the placenta is too small, is a frequent culprit for inconclusive or false-negative results. Maternal conditions also play a role: chromosomal abnormalities in the pregnant person’s own cells, maternal mosaicism, the presence of a vanishing twin, and even undiagnosed tumors can distort the signal.⁸

Body Weight and Fetal Fraction

One of the most consistent findings in the NIPT literature is that higher maternal body mass index lowers the fetal fraction. In one study, obese women had an average fetal fraction of about 9.2% compared to 12.5% in controls, and their rate of inconclusive results was more than six times higher.⁹ Interestingly, the total amount of cell-free DNA in the blood was not different between obese and normal-weight groups, suggesting the issue is not that obese people release more of their own DNA but that the relative share belonging to the placenta shrinks. On some screening platforms that set a minimum fetal fraction threshold, failure rates in obese women have been reported as high as 24%.¹⁰

Gestational age also matters, though its effect is subtler: the fetal fraction rises by only about 0.1% per week on average between weeks 10 and 21.¹⁰ Waiting an extra week or two before retesting can sometimes help if a first draw comes back inconclusive, but the improvement is marginal. Similarly, cell-free DNA studies have confirmed that pregnancies with trisomy 13 or 18 tend to have lower fetal fractions because those conditions compromise placental development, while trisomy 21 pregnancies may actually have slightly elevated fetal fraction.

The Unique Challenges of Sex Chromosome Screening

NIPT can also flag sex chromosome aneuploidies like Turner syndrome (45,X), Klinefelter syndrome (47,XXY), Triple X syndrome (47,XXX), and 47,XYY. As a group, sex chromosome aneuploidies occur more frequently than any single autosomal trisomy, affecting roughly 1 in 400 births.¹¹ But the positive predictive value for these conditions is substantially lower than for trisomy 21, 18, or 13.

Turner syndrome is the most problematic. Across multiple studies, the positive predictive value for a 45,X call on NIPT has landed in the range of about 21% to 29%, meaning roughly three out of four positive results turn out to be wrong after diagnostic follow-up.¹²¹³ Several factors contribute to this poor performance. Because the X chromosome carries over a thousand genes and shares only a small number of homologous sequences with the Y chromosome, even minor sequencing artifacts or mosaicism in placental tissue can produce misleading results. Klinefelter syndrome and Triple X tend to perform better, with positive predictive values in the 75% to 100% range, though sample sizes in many studies are small.

Expanded Panels and Microdeletions

Some commercial NIPT products now offer screening for microdeletions, which are small missing segments of chromosomes associated with conditions like 22q11.2 deletion syndrome (DiGeorge syndrome), 1p36 deletion syndrome, cri-du-chat, Prader-Willi, and Angelman syndrome. These are rarer than the major trisomies, and the screening performance is weaker. In a large retrospective study of over 80,000 referrals, the positive predictive value for 22q11.2 deletion syndrome was initially about 16%, though a revised protocol that re-sequenced high-risk calls at greater depth pushed it up to about 44%.¹⁴ For the other four microdeletion syndromes combined, the original positive predictive value was just 5%, improving to about 32% with the revised protocol.

The core difficulty is that microdeletions are small. Simulation studies have shown that when the deleted segment is under 1 megabase, standard low-coverage sequencing picks it up poorly. Sensitivity climbs to over 99% when the fetal fraction exceeds 10% and the deletion spans at least 3 megabases, but those conditions are not always met in real-world samples.¹⁵ This is why many professional societies and genetic counselors caution against treating expanded-panel results with the same confidence as trisomy 21 results.

Diagnostic Testing After a Positive Screen

No matter which screening test produces a high-risk result, the next step is a diagnostic procedure if the pregnant person chooses to pursue it. The two options are chorionic villus sampling (CVS), performed in the first trimester, and amniocentesis, usually done in the second trimester. Both involve collecting fetal cells and directly analyzing the chromosomes, giving a definitive answer rather than a probability.

The historical concern about these procedures has always been the risk of pregnancy loss. Older estimates put the miscarriage risk at roughly 1 in 100 to 1 in 200, which made many families hesitant. More recent data paints a reassuring picture. A large study comparing women who had CVS or amniocentesis with matched controls found no statistically significant increase in miscarriage risk attributable to either procedure. The procedure-related risk of loss after CVS was estimated at about 0.29%, and after amniocentesis the estimate was effectively zero, with the confidence interval spanning both slightly negative and slightly positive values.¹⁶ Another cohort study found pregnancy loss rates of about 1% after CVS and under 1% after amniocentesis, similar to rates in control groups who had no invasive procedure.¹⁷ These numbers suggest the added risk from modern invasive procedures is far smaller than what many people assume.

Preimplantation Genetic Testing

For people undergoing in vitro fertilization, aneuploidy screening can happen before a pregnancy even begins. Preimplantation genetic testing for aneuploidies (PGT-A) involves removing a small number of cells from the outer layer of an embryo at the blastocyst stage, typically five to eight cells from the trophectoderm. Because this biopsy targets the trophectoderm rather than the inner cell mass, which becomes the fetus, it is considered less invasive to the developing embryo.¹⁸ One advantage of testing at the blastocyst stage is that embryos have already undergone some natural selection between day 3 and day 5 or 6, so fewer need to be biopsied. Mosaicism, where some cells in the embryo have normal chromosomes and others do not, is also lower at this stage, improving the reliability of the result.

When NIPT Detects Something Unexpected in the Mother

One of the stranger developments in aneuploidy screening has been the accidental detection of cancer in the pregnant person. Since NIPT works by analyzing all cell-free DNA in the blood, it can pick up chromosomal imbalances coming from tumor cells as well as from the placenta. These show up as bizarre patterns involving multiple chromosomes that do not match any known fetal aneuploidy, prompting laboratory flags and clinical investigation.¹⁹

These cases are rare but well-documented. The detection rate depends on both the biology of the tumor and the specific NIPT technology used. Multiple chromosomal copy-number changes in the cell-free DNA are a particularly strong signal.²⁰ This is not something NIPT is designed for, and no one should treat it as a cancer screening tool, but it is an incidental benefit that has led to early detection of malignancies in some pregnant individuals who had no symptoms.

The Biology Behind Aneuploidy

Understanding why aneuploidies occur in the first place helps make sense of who is at higher risk and why screening exists. The most common cause is a failure of chromosomes to separate properly during egg or sperm formation, a process called nondisjunction. For most autosomal trisomies, errors during maternal meiosis account for the majority of cases, and errors in the first meiotic division are the most frequent single class. But the pattern varies by chromosome: trisomy 16 arises almost entirely from maternal meiosis I errors, while trisomy 18 more often involves meiosis II mistakes.²¹

Maternal age is the strongest known risk factor, and research on chromosome 21 has helped explain part of that link. The placement of genetic crossover events along the chromosome interacts with age-related changes in the egg cell. A crossover near the center of the chromosome’s long arm appears to interact with age-related risk factors to increase errors during the second meiotic division.²² These biological details underpin the reason screening recommendations have historically been tied to maternal age, though current guidelines in most countries now offer screening to everyone regardless of age.

The consequences of an extra chromosome vary enormously depending on which one is involved. Trisomy 21 is the most survivable of the common autosomal trisomies, with many affected individuals living into adulthood. Trisomies 13 and 18 are far more severe; most affected pregnancies end in miscarriage, and those that survive birth rarely live beyond early childhood.²³

Counseling and Informed Consent

The simplicity of NIPT has created an ethical tension. Because it requires only a blood draw and performs well, it can feel routine, and some researchers have raised concerns that this procedural ease makes it harder for patients to recognize they are making a meaningful choice about genetic information they may or may not want.²⁴ In qualitative research, some women have described feeling unprepared for what a positive result would mean emotionally and practically, pointing to gaps in how genetic information is communicated during prenatal care.²⁵

One emerging proposal in the ethics literature is the concept of “just-in-time consent.” The idea is that most people who screen negative never need to engage deeply with what a positive result would mean, and requiring intensive pre-test counseling for everyone is both impractical in resource-limited settings and often unwanted by patients. Instead, the heavy counseling and support resources would be concentrated after a positive result, when families report needing it most.²⁶

Cost, Access, and Regulation

NIPT is widely available in high-income countries, but access remains uneven globally. Cost is one of the largest barriers. A cost-effectiveness analysis from Brazil’s private health system found that adding NIPT as an initial screen reduced amniocentesis use by about 18% and lowered procedure-related pregnancy losses, but the incremental cost per patient was substantial.²⁷ Modeling studies suggest that how NIPT fits into a country’s screening pathway matters enormously: using it as a secondary screen for people who already tested high-risk on traditional screening tends to be more cost-effective than offering it to everyone as a first-line test, particularly in countries where the price of NIPT remains high.²⁸ One analysis estimated that universal first-line NIPT would only become the most cost-effective strategy if the test price fell below about $47.

In the United States, NIPT exists in a regulatory gray zone. The tests are classified as laboratory-developed tests, which means they are not subject to the same premarket approval process the FDA applies to other medical devices.²⁹ Different companies market their tests under different brand names with varying expanded panels, and there is no standardized requirement for how results are reported to patients. This commercial landscape, combined with the complexity of positive predictive values that shift depending on risk group, means the gap between what people understand about their results and what those results actually mean can be wide. Informed choice, as a global review noted, remains hampered by cost barriers, decision-making complexity, and a shortage of resources that promote genuine understanding of what screening does and does not tell you.³⁰